A Multicenter Phase 2, 12-week Double-blind, Placebo-controlled, Randomized, Parallel-group Study of JZP150 for the Treatment of Posttraumatic Stress Disorder
Latest Information Update: 10 Jan 2024
At a glance
- Drugs JZP 150 (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals plc
- 05 Jan 2024 Status changed from active, no longer recruiting to completed.
- 21 Dec 2023 Topline results presented in the Jazz Pharmaceuticals Media Release.
- 21 Dec 2023 According to a Jazz Pharmaceuticals media release, Primary endpoint (Mean Change from Baseline to Week 12 in Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS-5) Total Symptom Severity Score) has not been met.